Gregory Naeve will become Bellicum Pharmaceuticals Inc.'s chief business officer Aug. 21.
Naeve was previously immuno-oncology and cell therapy lead for Pfizer Inc.'s external research and development unit.
Bellicum Pharmaceuticals appoints chief business officer
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Gregory Naeve will become Bellicum Pharmaceuticals Inc.'s chief business officer Aug. 21.
Naeve was previously immuno-oncology and cell therapy lead for Pfizer Inc.'s external research and development unit.